A six-month competition hosted by NeuroAge Therapeutics with TruDiagnostic, Vero Bioscience, Harvard FaceAge and collaborating academic labs will measure participants across epigenetic, proteomic, imaging, facial and functional age markers, then repeat the identical panel after a self-directed intervention period. Because every entrant receives the same multi-modal battery, the design produces rare side-by-side data on whether independent aging clocks agree with one another and whether they move in response to behavior change. Awards recognize both the largest reduction in measured biological age and the lowest biological age relative to chronological age.
Key Points
- Identical multi-clock panel applied before and after six-month intervention period
- Epigenetic, proteomic, brain MRI, facial and functional measures compared directly
- Field still lacks consensus on what individual clocks actually measure
Longevity Analysis
Hundreds of aging clocks now exist, several are already being used as trial endpoints, and their relationship to one another remains largely uncharacterized — a reanalysis of Insilico Medicine's rentosertib trial reported patients reading 2.7 to 3.5 years younger on six proteomic clocks while acknowledging that treating a diseased lung cannot yet be separated from slowing aging. Running cognitive testing, methylation and protein panels, volumetric brain imaging, aerobic capacity, grip strength and sit-to-stand on the same individuals across the same interval is how measurement error gets separated from genuine signal, and how a number on a report becomes something a clinician can act on. The wider objective remains compressing the interval of late-life illness, where a single healthy year added at population scale has been valued at roughly 38 trillion dollars and a five-year delay in dementia onset would reduce prevalence by approximately 41 percent.
Original published by Longevity.Technology, by Guest Contributor.